NO20005037L - Paroksetinmaleat - Google Patents

Paroksetinmaleat

Info

Publication number
NO20005037L
NO20005037L NO20005037A NO20005037A NO20005037L NO 20005037 L NO20005037 L NO 20005037L NO 20005037 A NO20005037 A NO 20005037A NO 20005037 A NO20005037 A NO 20005037A NO 20005037 L NO20005037 L NO 20005037L
Authority
NO
Norway
Prior art keywords
paroksetinmaleat
depression
prevention
preparation
treatment
Prior art date
Application number
NO20005037A
Other languages
Norwegian (no)
Other versions
NO20005037D0 (en
Inventor
Victor Witold Jacewicz
David Alan Jones
John Man
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807627.6A external-priority patent/GB9807627D0/en
Priority claimed from GBGB9823856.1A external-priority patent/GB9823856D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20005037D0 publication Critical patent/NO20005037D0/en
Publication of NO20005037L publication Critical patent/NO20005037L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Abstract

Paroksetinmaleat og dets fremstilling og anvendelse ved behandlingen og forebyggelse av bl.a. depresjon er beskrevet.Paroxetine maleate and its preparation and use in the treatment and prevention of e.g. Depression is described.

NO20005037A 1998-04-09 2000-10-06 Paroksetinmaleat NO20005037L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9807627.6A GB9807627D0 (en) 1998-04-09 1998-04-09 Novel compounds
GBGB9823856.1A GB9823856D0 (en) 1998-10-30 1998-10-30 Novel compound
PCT/GB1999/001106 WO1999052901A1 (en) 1998-04-09 1999-04-09 Paroxetine maleate

Publications (2)

Publication Number Publication Date
NO20005037D0 NO20005037D0 (en) 2000-10-06
NO20005037L true NO20005037L (en) 2000-12-05

Family

ID=26313449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005037A NO20005037L (en) 1998-04-09 2000-10-06 Paroksetinmaleat

Country Status (18)

Country Link
EP (1) EP1073652A1 (en)
JP (1) JP2002511466A (en)
KR (1) KR20010042552A (en)
CN (1) CN1305474A (en)
AP (1) AP2000001950A0 (en)
AU (1) AU3433499A (en)
BG (1) BG104914A (en)
BR (1) BR9909529A (en)
CA (1) CA2327450A1 (en)
EA (1) EA200001050A1 (en)
HU (1) HUP0103651A3 (en)
ID (1) ID26879A (en)
IL (1) IL138920A0 (en)
NO (1) NO20005037L (en)
PL (1) PL343378A1 (en)
SK (1) SK15032000A3 (en)
TR (1) TR200002939T2 (en)
WO (1) WO1999052901A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
NL1017421C2 (en) 2001-02-21 2002-01-15 Synthon Bv Process for the production of paroxetine.
KR100672184B1 (en) 2004-09-21 2007-01-19 주식회사종근당 Paroxetine cholate or cholic acid derivative salts
ITTO20060143A1 (en) * 2006-02-28 2007-09-01 Bridgestone Corp TIRE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0994872B9 (en) * 1997-06-10 2001-12-05 Synthon B.V. 4-phenylpiperidine compounds

Also Published As

Publication number Publication date
ID26879A (en) 2001-02-15
PL343378A1 (en) 2001-08-13
NO20005037D0 (en) 2000-10-06
CA2327450A1 (en) 1999-10-21
WO1999052901A1 (en) 1999-10-21
SK15032000A3 (en) 2001-04-09
CN1305474A (en) 2001-07-25
TR200002939T2 (en) 2001-02-21
AP2000001950A0 (en) 2000-12-31
HUP0103651A3 (en) 2002-12-28
IL138920A0 (en) 2001-11-25
AU3433499A (en) 1999-11-01
BG104914A (en) 2001-10-31
EA200001050A1 (en) 2001-04-23
KR20010042552A (en) 2001-05-25
JP2002511466A (en) 2002-04-16
BR9909529A (en) 2000-12-12
EP1073652A1 (en) 2001-02-07
HUP0103651A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
DE69105501T2 (en) (+) - ALPHA- (2,3 DIMETHOXYPHENYL) -1- [2- (FLUOROPHENYL) ETHYL] -4-PIPERIDINE METHANOL.
DE60124684D1 (en) SULPHONAMIDO-SUBSTITUTED BROKEN BICYCLOALKYL DERIVATIVES
CL2004001174A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING: 1- (4-FLUOROPHENYL) -3 (R) - [3- (4-FLUOROPHENYL) -3 (S) -HYDROXIPROPIL] -4 (S) - (4-HYDROXIFENYL) -2-ACETIDINONE ( EZETIMIBA) AND EXCIPIENTS; AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROSIS, HIPERCOLESTEROLEMIA, DAY
DE69708149D1 (en) DOUBLE CHAMBER CONTAINER AND SINGLE CHAMBER THEREFOR
GB2342657B (en) Derivatization of polymers and well treatments using same
NO20003488D0 (en) Homopolymers and copolymers of ethylene
ID21863A (en) COMPOUNDS OF KINOLIN AND KINAZOLIN USED IN THERAPY, SPECIFICALLY IN TREATMENT OF TYPICAL PROSTATIC HEPERPLASIA
PT1100459E (en) PREPARATION OF OLEOSA ESPUMANTE AND ITS USE
NO20020567D0 (en) Process for the preparation and use of ozone-enriched water
DK0832104T3 (en) Dolastatin derivatives, their preparation and use
NO20001412D0 (en) Compositions and Methods in the Treatment of Respiratory Disorders
NO20005037L (en) Paroksetinmaleat
NO984836L (en) Substituted benzylamines and their use in the treatment of depression
NO994257D0 (en) Use of levobupivacaine in facial surgery
IL148202A0 (en) Copolymers and methods of treating prion-related diseases
ZA972345B (en) Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders.
AU2002227247A1 (en) Biofilm therapy process and elements
IL131085A0 (en) The use of levobupivacaine or ropivacaine in treating migraine
EE200000290A (en) Combination of active substances, namely tetrahydropyridines and acetylcholinesterase inhibitors, for the treatment of senile dementia of the Alzheimer's disease type
AU3022201A (en) Novel use of (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)- chromane and its physiologically aceptable salts
AU1295099A (en) Water repellent restorative and process of use
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
TR200003084T2 (en) Paroxetine ascorbate
AU2001228790A1 (en) A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enthalt

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application